WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY® 04 January 2021
Pfizer and BioNTech to supply the U.S. with 100 million additional doses of COVID-19 vaccine 23 December 2020
Pfizer and BioNTech receive authorization in the European Union for COVID-19 vaccine 21 December 2020
Pfizer and BioNTech receive CHMP positive opinion for their COVID-19 vaccine 21 December 2020
Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19 14 December 2020
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first Emergency Use Authorization for vaccine to combat COVID-19 in the U.S. 11 December 2020
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial of BNT162b2 COVID-19 vaccine candidate in The New England Journal of Medicine 10 December 2020
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to combat COVID-19 09 December 2020
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19 02 December 2020
Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine 20 November 2020
Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints 18 November 2020
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study 09 November 2020
BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2 06 October 2020
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial 14 September 2020
Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19 09 September 2020
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19 21 August 2020
Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19 11 August 2020
Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate 31 July 2020
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study 28 July 2020
Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2 27 July 2020
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer invests $43 billion to battle cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.